Drug intelligence / Profile preview

ATH-272

Development stage: Preclinical
Lead developer: Athos Therapeutics
Modality: Small Molecules

Overview

ATH-272 is a small molecule drug candidate developed by Athos Therapeutics. It is being investigated as an FLT3 inhibitor for the treatment of acute myeloid leukemia (AML). The compound is in preclinical development, with plans to advance into Phase 1 clinical trials for AML. Its mechanism of action involves targeting the FLT3 protein, which plays a key role in the proliferation and survival of leukemic cells. The drug is part of Athos Therapeutics' oncology pipeline focused on neoplasms and hemic and lymphatic diseases[1][2][3].

Targets

FLT3 (Fms related receptor tyrosine kinase 3)

Beyond the preview

Go deeper on ATH-272.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATH-272.

Explore the full profile